These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16708557)

  • 21. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.
    Takatori R; Takahashi KA; Tokunaga D; Hojo T; Fujioka M; Asano T; Hirata T; Kawahito Y; Satomi Y; Nishino H; Tanaka T; Hirota Y; Kubo T
    Clin Exp Rheumatol; 2006; 24(5):546-54. PubMed ID: 17181924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.
    Schotte H; Schmidt H; Gaubitz M; Drynda S; Kekow J; Willeke P; Schlüter B
    Clin Rheumatol; 2015 Dec; 34(12):2021-8. PubMed ID: 26526676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.
    Criswell LA; Lum RF; Turner KN; Woehl B; Zhu Y; Wang J; Tiwari HK; Edberg JC; Kimberly RP; Moreland LW; Seldin MF; Bridges SL
    Arthritis Rheum; 2004 Sep; 50(9):2750-6. PubMed ID: 15457442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-18 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Kurzawski M; Czerny B; Gawronska-Szklarz B; Drozdzik M; Herczynska M
    Tissue Antigens; 2006 May; 67(5):415-8. PubMed ID: 16671950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-10 gene promoter polymorphism in Polish rheumatoid arthritis patients.
    Paradowska-Gorycka A; Trefler J; Maciejewska-Stelmach J; Łacki JK
    Int J Immunogenet; 2010 Aug; 37(4):225-31. PubMed ID: 20477882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
    Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M
    Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis.
    Lard LR; van Gaalen FA; Schonkeren JJ; Pieterman EJ; Stoeken G; Vos K; Nelissen RG; Westendorp RG; Hoeben RC; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Rheum; 2003 Jul; 48(7):1841-8. PubMed ID: 12847677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment.
    Iwaszko M; Świerkot J; Kolossa K; Jeka S; Wiland P; Bogunia-Kubik K
    Joint Bone Spine; 2016 Jan; 83(1):75-9. PubMed ID: 26453102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.
    Kumagai K; Hiyama K; Oyama T; Maeda H; Kohno N
    Int J Mol Med; 2003 May; 11(5):593-600. PubMed ID: 12684695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis.
    Todoerti M; Scirè CA; Boffini N; Bugatti S; Montecucco C; Caporali R
    Ann N Y Acad Sci; 2010 Apr; 1193():139-45. PubMed ID: 20398020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.
    Nesher G; Osborn TG; Moore TL
    Clin Exp Rheumatol; 1997; 15(4):343-7. PubMed ID: 9272292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of the -1082 G/A promoter polymorphism of interleukin-10 gene with the autoantibodies production in patients with rheumatoid arthritis.
    Nemec P; Pavkova-Goldbergova M; Gatterova J; Fojtik Z; Vasku A; Soucek M
    Clin Rheumatol; 2009 Aug; 28(8):899-905. PubMed ID: 19308651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis.
    Pawlik A; Florczak M; Ostanek L; Brzosko M; Brzosko I; Szklarz BG
    Scand J Rheumatol; 2005; 34(1):22-6. PubMed ID: 15903021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
    Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S
    Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.